Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06315491

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Sponsor: Cybrexa Therapeutics

Conditions Platinum-resistant Ovarian Cancer Refractory Ovarian Carcinoma

Interventions CBX-12

Updated 7 times since 2024 Last updated: Oct 2, 2025 Started: Sep 25, 2024 Primary completion: Oct 31, 2025 Completion: Oct 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06315491, this PHASE2 trial focuses on Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma and remains actively recruiting participants. Sponsored by Cybrexa Therapeutics, it has been updated 7 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cybrexa Therapeutics

Data source: Cybrexa Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cleveland, United States , Covington, United States , Dallas, United States , Dyer, United States , Eugene, United States , Los Angeles, United States , Louisville, United States , Margate, United States , New Haven, United States , New York, United States and 6 more locations